Hillsdale Investment Management Inc. Buys 42,570 Shares of Johnson & Johnson $JNJ

Hillsdale Investment Management Inc. increased its stake in Johnson & Johnson (NYSE:JNJ) by 1,942.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,762 shares of the company’s stock after acquiring an additional 42,570 shares during the period. Hillsdale Investment Management Inc.’s holdings in Johnson & Johnson were worth $6,837,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. GFG Capital LLC purchased a new position in shares of Johnson & Johnson in the second quarter worth $35,000. Stone House Investment Management LLC bought a new stake in Johnson & Johnson in the 1st quarter worth $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson in the 1st quarter worth $48,000. Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson in the first quarter valued at about $52,000. Finally, Pandora Wealth Inc. purchased a new stake in shares of Johnson & Johnson during the first quarter worth about $65,000. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.4%

NYSE JNJ opened at $203.29 on Friday. The firm has a market capitalization of $489.77 billion, a PE ratio of 19.62, a P/E/G ratio of 2.19 and a beta of 0.38. The stock’s 50 day moving average is $187.74 and its 200 day moving average is $171.22. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $204.51. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. Research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.6%. Johnson & Johnson’s payout ratio is presently 50.19%.

Analysts Set New Price Targets

JNJ has been the topic of a number of research analyst reports. Raymond James Financial boosted their price target on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. HSBC increased their price objective on Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, October 16th. Citigroup upped their target price on Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, October 15th. Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Finally, Argus set a $210.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.